The Effect of Neutrophil Lymphocyte Ratio on Prognosis of Ovarian Cancer.

Öz

Objective: In this study, we planned to investigate the association between neutrophil lymphocyte ratio (NLR) and prognosis in ovarian cancer. Materials And Methods: The data of 84 patients who were followed up at Manisa Celal Bayar University Medical Oncology Clinic between May 2011 and November 2018 were analyzed retrospectively. NLR was calculated by dividing absolute neutrophil count by absolute lymphocyte count. The cut-off value of NLR was 4.2 according to the result of ROC analysis and the patients were divided into two groups as <4.2 and ≥4.2. These groups were compared with regard to overall survival (OS) and progression free survival (PFS) rates. Results: Preoperative neutrophil and lymphocyte values were examined from 71 of 84 patients. OS in all study population was 20 months (95% CI: 8,3-31,6, std: 5,9). There was no significant difference between two groups in OS rates (p: 0.279). PFS of 47 (66%) patients with an NLR of less than 4.2 was found to be 31 months and PFS was 21 months in 27 (29.2%) patients with a value higher than 4.2, and was statistically significant (p ; 0,010). Conclusion: The results of our study indicate that pre-treatment high NLR is associated with poor prognosis in ovarian cancer patients.

Anahtar Kelimeler

• Ovarian Cancer,Neutrophil Lymphocyte Ratio,Prognosis

Nötrofil Lenfosit Oranının Over Kanserinin Prognozuna Etkisi.

Öz

Amaç: Bu çalışmada over kanserinde nötrofil lenfosit oranı (NLR) ile prognoz arasındaki ilişkiyi araştırmayı planladık. Gereç ve Yöntem: Mayıs 2011-Kasım 2018 tarihleri arasında Manisa Celal Bayar Üniversitesi Tıbbi Onkoloji Kliniğinde takip edilen 84 hastanın verileri retrospektif olarak incelendi. NLR, mutlak nötrofil sayısının mutlak lenfosit sayısına bölünmesiyle hesaplanmıştır. ROC analizi sonucuna göre NLR'nin cut-off değeri 4.2 idi ve hastalar <4.2 ve >4.2 olarak iki gruba ayrıldı. Bu gruplar genel sağkalım (OS) ve progresyonsuz sağkalım (PFS) oranları açısından karşılaştırıldı. Bulgular: 84 hastanın 71'inde preoperatif nötrofil ve lenfosit değerleri incelendi. Tüm çalışma popülasyonunda OS 20 aydı (% 95 GA: 8,3-31,6, std: 5,9). İki grup arasında OS oranları arasında anlamlı fark yoktu (p: 0.279). NLR'si 4.2'den az olan 47 hastanın (% 66) PFS'si 31 ay, PFS değeri 4.2'den yüksek olan 27 (% 29.2) hastada 21 aydı ve istatistiksel olarak anlamlıydı (p; 0,010). Sonuç: Çalışmamızın sonuçları yüksek tedavi öncesi yüksek NLR'nin over kanseri hastalarında kötü prognoz ile ilişkili olduğunu göstermektedir.

Anahtar Kelimeler

• over kanseri,nötrofil lenfosit oranı,prognoz

Kaynakça

1. 1- Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. 2012;12:298–306
2. 2- Huang A, Cao S, Tang L. The tumor microenvironment and inflammatory breast cancer. J Cancer 2017; 8(10):1884-1891
3. 3- Qi-tao, Huang, et al. "Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies." Cellular Physiology and Biochemistry 41.6 (2017): 2411-2418.
4. 4- Chen J, Deng Q, Pan Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio. 2015;5:502–507. Published 2015 May 12. doi:10.1016/j.fob.2015.05.003
5. 5- Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
6. 6- Corthay A. Does the immune system naturally protect against cancer? Front. Immunol. 2014;5:197.
7. 7- Marisa L, Svrcek M, Collura A, et al. the balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J Natl Cancer Inst 2018; 110. doi: 10.1093/jnci/djx136.
8. 8- Dirican, Ahmet, et al. "Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha." Asian Pacific journal of cancer prevention 14.3 (2013): 2101-2105.

9. 9- Cho, HanByoul, et al. "Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment." Cancer immunology, immunotherapy 58.1 (2009): 15-23.
10. 10- Huang, Qi-tao, et al. "Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: a systematic review and meta-analysis of observational studies." Cellular Physiology and Biochemistry 41.6 (2017): 2411-2418.
11. 11- Chen, Gaowen, et al. "Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis." Technology in cancer research & treatment 17 (2018): 1533033818791500.
12. 12- Zhao, Zhe, et al. "Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies." Archives of Gynecology and Obstetrics 297.4 (2018): 849-857.
13. 13- Chen, Shubo, et al. "Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker in patients with ovarian cancer: a meta-analysis." BioMed research international 2017 (2017).
14. 14- Nakano K., Hosoda M., Yamamoto M., Yamashita H. Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer. Anticancer Res. 2014;34:3819–3824.
15. 15- Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. 2012;12:298–306